NIOD CAIS3 vs. The Ordinary copper peptide serum
Compare NIOD CAIS3 and The Ordinary copper serum with a draft critical review of ingredient benefits, documented reactions, long-term evidence gaps and price limitations. Scientific evidence is kept separate from label claims.
Multi-Peptide + Copper Peptides 1% Serum
30 mL · Facial serum
$32.00USD · Recorded 2026-10-18
What matters in 30 seconds.
The key findings, without the chemistry lesson.
What is documented?
The labels use different copper-peptide names. Their other selected peptides also differ; the names alone do not establish chemical equivalence.[8][7]
Manufacturer labels
See ingredient differencesWhat does it mean for your purchase?
Compare the recorded 30 mL prices and cost per mL below. The price difference measures cost, not an established extra benefit from NIOD.[8][7]
Recorded prices · not a performance ranking
Understand the priceWhat has not been demonstrated?
The selected research does not establish which finished serum works better or is safer. Ingredient studies and scoped safety assessments cannot answer that comparison by themselves.[1][6][5]
Editorial interpretation of selected research
Check the evidenceBefore you choose: neither finished formula is established as safer or more effective by this review. If you have a confirmed ingredient allergy, check the full label before buying.
Understand the evidenceIngredients, price and the gaps.
Compare selected label facts. Tap an ingredient to understand its name.
Compare recorded facts side by side. Missing information is not a negative rating.
| Compare the detailsTwo products. The same questions. | ||
|---|---|---|
| Product basics | ||
| Presentation | 30 mL | 30 mL |
| Format | Water-based serum | Water-based serum |
| How the brand says to use it | Directions not recorded. Read the manufacturer's current instructions.Manufacturer directions, not a personalized routine. | Directions not recorded. Read the manufacturer's current instructions.Manufacturer directions, not a personalized routine. |
| Price & value | ||
| Recorded price | $93.00 USDPrice recorded Excludes tax and shipping. | $32.00 USDPrice recorded Excludes tax and shipping. |
| Price per mL | $3.10 / mL | $1.07 / mL |
| What it contains and what it means | ||
| Peptides, explained Peptides are small chains of the building blocks used in proteins. Their names identify ingredients, not quality scores. Open an explanation to learn what each one means. |
|
|
| How much of each ingredient? A formula is the whole mix. A blend percentage does not tell us the amount of every ingredient. | The brand describes two peptide components at 1% each. This does not reveal the amount of every named ingredient.Manufacturer disclosure; not independently measured.Individual amounts not verified | The product name states 1% copper peptides. Amounts of the other selected peptides are not recorded.Manufacturer disclosure; not independently measured.Individual amounts not verified |
| Sources & limits | ||
| What we still cannot know | Not established
| Not established
|
| Label source | NIOD manufacturer label Label checked Label checked; not a clinical review. | The Ordinary manufacturer label Label checked Label checked; not a clinical review. |
Prices are dated USD observations. Ingredient selections are incomplete; matching names do not establish equivalent formulas or results.
What do the label differences mean?Exact names, disclosures and cost limits
Start with the exact copper name
NIOD lists Tripeptide-1 Copper Acetate; The Ordinary lists Copper Tripeptide-1. The word copper alone does not establish identical ingredients or performance.[8][7]
Other selected peptides also differ
NIOD lists Tripeptide-29 and Acetyl Tetrapeptide-2; The Ordinary lists Acetyl Hexapeptide-8 and palmitoyl peptides. Open the explanations to understand the names; do not treat the count as a quality score.[8][7]
Compare the exact 30 mL bottles
NIOD’s US site showed USD 93 after selecting 30 mL on 2026-10-20. The initial 15 mL selection showed USD 62 and is not the price used here. Recorded prices exclude tax and shipping and do not measure clinical benefit.[8]
Documented differences
NIOD lists Tripeptide-1 Copper Acetate; The Ordinary lists Copper Tripeptide-1. These exact label names are retained without asserting molecular or clinical equivalence. The Ordinary also lists Acetyl Hexapeptide-8; NIOD lists Tripeptide-29. The ingredient selections shown here are incomplete.[8][7]
Use this comparison for your decision
If your question is whether the copper names are equivalent
The exact names differ in the recorded labels. This comparison preserves them separately rather than treating both as the same ingredient.[8][7]
If you are comparing value
Compare the dated prices and price per mL for the two 30 mL bottles. The NIOD price was observed on 2026-10-20; The Ordinary price has its own observation date. A higher price is not evidence of better outcomes.
Evidence, explained.
What do the source labels mean?
Human studies describe what happened in their participants and tested preparation. Laboratory studies examine a model, not clinical results in shoppers. Case reports describe individual events, not how often they occur.
Safety assessments review specified uses and concentrations. Manufacturer labels identify recorded product facts. Neither is a guarantee of results or individual tolerance. Source type is not a quality score.
Benefits: ingredient evidence is not a product promise
Source type: Human ingredient study · Laboratory study
A benefit signal exists for Argireline; superiority of either copper serum is not established here.[1][2]
Read the evidence and what it means
Source type: Human ingredient study
A randomized placebo-controlled Argireline study in 60 Chinese participants reported improvement in eye-area wrinkle measures after four weeks. It did not identify these two retail serums as the tested treatment.[1]
Different study preparation. Not a test of either compared serum.
Source type: Laboratory study
A separate laboratory study on human cadaver and guinea-pig skin found limited penetration of acetyl hexapeptide-8 from its tested emulsion. This was a 24-hour experiment, not a clinical wrinkle trial; it cannot prove these serums work or do not work.[2]
Different study preparation. Not a test of either compared serum.
Editorial interpretation
For this purchase, ingredient research is a starting point. We have not established a head-to-head clinical result for NIOD versus The Ordinary. Do not pay extra on the assumption that a more expensive copper serum has proven superior results.
Risks: look beyond the peptide
Source type: Case report · Regulatory safety opinion · Safety assessment
Preservative reactions are documented, but their likelihood in these serums is unknown.[3][4][5]
Read the evidence and what it means
Source type: Case report
A 2024 clinical report describes two cases of contact urticaria—hives after skin contact—from phenoxyethanol in other cosmetics. A case report documents a possible reaction, not how frequently it occurs or that either serum caused it.[3]
Source type: Regulatory safety opinion
The EU Scientific Committee on Consumer Safety concluded that phenoxyethanol is safe as a cosmetic preservative up to 1.0% under its assessment. That is not a guarantee of individual tolerance or an assay of these US products.[4]
Editorial interpretation
The label check below identifies phenoxyethanol in both formulas. If you have a confirmed allergy to it, that is a concrete reason to discuss alternatives with your clinician. Ingredient presence alone cannot diagnose an allergy or establish that one of these products is riskier.
Source type: Safety assessment
The 2025 Acetyl Hexapeptide-8 safety assessment reaches a favorable conclusion up to 0.005%, with insufficient data above that amount. This does not establish harm above it or certify a serum with an unverified pure-peptide concentration.[5]
Long-term use: a safety assessment has boundaries
Source type: Safety assessment
Neither a short trial nor an ingredient assessment establishes years of safety for these complete formulas.[6]
Read the evidence and what it means
Source type: Safety assessment
The CIR assessment includes Copper Tripeptide-1 and specified related peptides and concludes safe use under the practices and concentrations it reviewed. Its scope does not automatically cover every copper-named ingredient or either complete serum.[6]
Source type: Safety assessment
The inspected CIR report notes gaps in reproductive/developmental toxicity and carcinogenicity data for its reviewed group, while still reaching its scoped safe-use conclusion. A missing dataset is not evidence that these products cause those harms.[6]
Editorial interpretation
This review does not establish long-term harm or long-term safety for either finished serum. We have not performed an exhaustive search or a clinical safety review. We also do not transfer injection, ingestion or microneedling findings to normal cosmetic application on intact skin.
Value: what would justify paying more?
Editorial interpretation
A price premium is not evidence of a health or performance advantage.
Read the evidence and what it means
Editorial interpretation
The inspected studies and safety assessments do not compare the two finished products. They cannot establish that paying more buys better wrinkle reduction, lower allergy risk or greater long-term safety.
Editorial interpretation
NIOD’s exact 30 mL price is now recorded at USD 93 on 2026-10-20. Compare that dated observation with The Ordinary’s own recorded price and date. Neither the price difference nor ingredient research establishes an extra clinical benefit; texture and wear have not been tested by Peptivelo.
Which label facts connect this research to these products?
Source type: Manufacturer label
The current US ingredient lists for both products name Phenoxyethanol and Chlorphenesin. These are additional label checks, not additions to our selected-peptide list. Individual preservative concentrations are not given in the inspected lists. The academic phenoxyethanol case report concerns different cosmetics; it is not an adverse-event report for these two serums. NIOD also advertises product tests with 31–32 people over 4–12 weeks. We have not assessed their full protocols or an independently published head-to-head result; these brand-reported claims are separate from the academic evidence above.[7][8]
Manufacturer links establish ingredient presence only. Scientific references support the research statements above. Formulas can change; check your purchased packaging.
Study dataDesign, sample, duration and what each source can tell us
For a closer look at the research behind this review. These sources answer different questions: they are not head-to-head tests of the two retail serums. Their results cannot be combined into a product ranking.
On smaller screens, scroll the table sideways. Open a numbered reference for access limits, funding context and source details.
| Source & design | Sample or model | Duration | Reported finding | How to interpret it |
|---|---|---|---|---|
| Human ingredient study2013[1] | 60 Chinese participants; randomized placebo-controlled ingredient study (3:1 allocation). | 4 weeks | The abstract reports improved eye-area wrinkle measures with Argireline relative to placebo. | Ingredient evidence; neither retail serum was identified as the tested product. |
| Laboratory study2015[2] | Human cadaver and hairless guinea pig skin in a laboratory diffusion model; no living human participants. | 24 hours | The abstract reports mostly surface-retained peptide and no detected peptide in the dermis under the tested conditions. | Penetration under the tested conditions; not a clinical benefit or safety trial. |
| Human case report2024[3] | 2 individual case reports involving other cosmetics; no comparison group. | Follow-up duration not recorded in the inspected summary | The repository summary describes contact urticaria associated with phenoxyethanol, with reactions at the face rather than other tested sites. | An allergy signal, not an estimate of how often reactions occur in either serum. |
| Regulatory safety opinion2016[4] | Regulatory assessment of multiple evidence sources; not one trial cohort. | Not applicable — evidence assessment | Provides the EU committee’s 1.0% preservative safety conclusion under its assessed conditions. | Preservative use up to 1% under the assessed conditions; not approval of these finished products. |
| Expert safety assessment2018[6] | Expert assessment of specified peptide identities and uses; not one trial cohort. | Not applicable — evidence assessment | The panel’s favorable conclusion is conditional on the reviewed uses, concentrations and peptide identities. | Limited to the identities, uses and concentrations reviewed; not proof of years of finished-formula safety. |
| Expert safety assessment2025[5] | Expert assessment of Acetyl Hexapeptide-8 cosmetic use, not a product trial. | Not applicable — evidence assessment | The 2025 panel gives a favorable conclusion up to 0.005% and finds data insufficient above that concentration. | Favorable conclusion up to 0.005%; insufficient data above that amount. Unknown pure-peptide amounts prevent a finished-serum safety conclusion. |
Reading limit: some records were checked through abstracts or repository summaries, not full papers. See each reference for exactly what was inspected. Scientific review remains pending.
Questions about these products
Does NIOD’s 1:1 mean the same as The Ordinary’s 1%?
Can this page tell me which copper serum works better?
Does a phenoxyethanol case report mean I should reject both serums?
Not on that evidence alone. The cases concern other cosmetics and do not give a reaction rate for these products. The SCCS safety conclusion has defined use conditions and does not guarantee individual tolerance. A known ingredient allergy is a separate reason to discuss suitable alternatives with your clinician.[3][4]
Check the original sources
Research and safety assessments are separate from manufacturer labels.
How this comparison was preparedScope, review status and limitations
What we cannot tell from the label
The selected label entries and inspected sources do not establish head-to-head clinical outcomes or years of safety for these complete formulas. Prices are dated observations for the exact 30 mL bottles, not live offers. Editorial and qualified scientific review remain pending.
Read our methodologyWhere to buy
Check the exact size, current price and shipping at the manufacturer.
No affiliate partnerships are active. Manufacturer links are ordinary links; we do not earn commissions from them. Recorded prices exclude tax and shipping and may have changed.
References
- Human ingredient study
Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. 2013. American Journal of Clinical Dermatology, 14(2), 147–153.
The Anti-Wrinkle Efficacy of Argireline, a Synthetic Hexapeptide, in Chinese Subjects: A Randomized, Placebo-Controlled StudyDOI: 10.1007/s40257-013-0009-9
Evidence and limitations for reference 1
- What was studied
- Randomized, placebo-controlled; 60 Chinese participants, 3:1 allocation, four weeks.
- What was reported
- The abstract reports improved eye-area wrinkle measures with Argireline relative to placebo.
- What this supports here
- An example of ingredient research with a defined population and duration, rather than a test of either compared copper serum.
- What it cannot establish
- Four weeks in one population. Neither CAIS3 nor The Ordinary’s copper serum is the tested product identified in the abstract. No product winner or long-term safety conclusion follows.
- Commercial context and disclosures
- The publisher reports no funding and no declared conflicts. These are author declarations, not an independent audit.
- What we inspected
- Publisher abstract and acknowledgments inspected; full methods behind subscription were not reviewed.
- Publication status check
- No correction or retraction notice was seen on the inspected publisher page. This is not a comprehensive integrity clearance.
- Laboratory study
Kraeling ME, Zhou W, Wang P, Ogunsola OA. 2015. Cutaneous and Ocular Toxicology, 34(1), 46–52.
In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulationDOI: 10.3109/15569527.2014.894521
Evidence and limitations for reference 2
- What was studied
- 24-hour in vitro diffusion experiment using human cadaver and hairless guinea-pig skin, not a human participant trial.
- What was reported
- The abstract reports mostly surface-retained peptide and no detected peptide in the dermis under the tested conditions.
- What this supports here
- Shows that the tested emulsion and skin model matter when interpreting peptide-delivery claims.
- What it cannot establish
- Not a living-person efficacy or long-term safety trial. Neither retail serum was tested.
- Commercial context and disclosures
- Authors have an FDA research affiliation. Funding and conflict declarations were not verified from the abstract; affiliation is not FDA product approval.
- What we inspected
- PubMed abstract and bibliographic metadata via Europe PMC; full methods not reviewed.
- Human case report
Marzola E, Melloni L, Caligiure A, Gianessi F, Bianchi A, Borghi A, Corazza M. 2024. Contact Dermatitis, 91(5).
Site-related contact urticaria from phenoxyethanolDOI: 10.1111/cod.14637
Evidence and limitations for reference 3
- What was studied
- Two clinical cases involving other cosmetics.
- What was reported
- The repository summary describes contact urticaria associated with phenoxyethanol, with reactions at the face rather than other tested sites.
- What this supports here
- Documents individual contact-urticaria reactions involving phenoxyethanol in other cosmetics.
- What it cannot establish
- Two cases cannot estimate incidence, establish the risk of either compared serum, or prove chronic systemic toxicity.
- Commercial context and disclosures
- Funding and conflict declarations were not verified in the accessible material.
- What we inspected
- University of Ferrara IRIS repository abstract retrieved 2026-10-20 at iris.unife.it. Linked full-text PDF returned 403; complete methods and declarations remain unverified.
- Regulatory safety opinion
Scientific Committee on Consumer Safety (SCCS). 2016. SCCS/1575/16, final version 6 October 2016.
Scientific opinion on phenoxyethanol — SCCS/1575/16Evidence and limitations for reference 4
- What this supports here
- Provides the EU committee’s 1.0% preservative safety conclusion under its assessed conditions.
- What it cannot establish
- Not a US product approval, a measurement of either formula, or a guarantee against an individual reaction. The opinion excludes non-cosmetic exposure.
- Commercial context and disclosures
- European Commission scientific advisory opinion; not published by a retailer.
- What we inspected
- Official SCCS conclusion and scope on the European Commission page; the underlying toxicology dossier was not independently reanalysed.
- Expert safety assessment
Johnson W Jr, Bergfeld WF, Belsito DV, et al. 2025. International Journal of Toxicology.
Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in CosmeticsDOI: 10.1177/10915818251340391
Evidence and limitations for reference 5
- What this supports here
- The 2025 panel gives a favorable conclusion up to 0.005% and finds data insufficient above that concentration.
- What it cannot establish
- Not evidence of harm above the assessed amount or certification of a complete serum. Pure-peptide concentrations in this comparison are unverified; blend percentages are not interchangeable.
- Commercial context and disclosures
- CIR assessment includes published and industry-submitted data. Article-specific funding and conflict statements were not verified in this pass; not government approval.
- What we inspected
- Publisher full-text introduction, abstract, composition and use-concentration sections inspected. Underlying toxicology datasets not independently reanalyzed.
- Expert safety assessment
Johnson W Jr, Bergfeld WF, Belsito DV, et al. 2018. International Journal of Toxicology.
Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in CosmeticsEvidence and limitations for reference 6
- What was studied
- Expert assessment of specified cosmetic peptide ingredients; underlying final report released June 30, 2014.
- What was reported
- The panel’s favorable conclusion is conditional on the reviewed uses, concentrations and peptide identities.
- What this supports here
- Provides a scoped safe-use conclusion for specified peptide identities, practices and concentrations.
- What it cannot establish
- Does not test these finished products or establish their safety over years. NIOD’s exact label name is not silently equated with a different name in the report.
- Commercial context and disclosures
- CIR is funded by the Personal Care Products Council and describes its panel/review process as independent. Industry-submitted data are included; this is not a government approval.
- Source organization and funding context
- What we inspected
- 2018 publisher full-text abstract, ingredient scope and introduction revisited; prior 2014 final-report discussion check retained. Not an independent toxicology reanalysis.
- Manufacturer labelMulti-Peptide + Copper Peptides US product label
Evidence and limitations for reference 7
- What this supports here
- Supports the selected peptide names, product name and 30 mL presentation.
- What it cannot establish
- Manufacturer claims and label checks do not establish clinical superiority over NIOD. Price observation dates are separate from this reference check.
- Commercial context and disclosures
- NIOD and The Ordinary are both DECIEM brands; these are commercial sources, not independent corroboration.
- What we inspected
- Public US product page
- Manufacturer labelCAIS3 US product label
Evidence and limitations for reference 8
- What this supports here
- Supports the exact selected peptide names and the brand’s description of its two-component disclosure.
- What it cannot establish
- Commercial source, not independent clinical corroboration. USD 93 was shown after selecting the 30 mL US variant on 2026-10-20; default 15 mL showed USD 62. Excludes tax and shipping; not a live offer or clinical advantage.
- Commercial context and disclosures
- NIOD and The Ordinary are both DECIEM brands; these are commercial sources, not independent corroboration.
- What we inspected
- US product page and browser-rendered size selection. Exact 30 mL / USD 93 screen captured in docs/research/niod-30ml-price-2026-10-20.png.